g0302-covid19
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 31, 2020 (NCT04527081)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - SARS-CoV-2
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650372 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04993586 | Phase 1/Phase 2 (Phase 2) | Jul 29, 2021 | AnGes, Inc., Japan Agency for Medical Research and Development |
| NCT04655625 | Phase 2/Phase 3 (Phase 3) | Nov 23, 2020 | AnGes, Inc., Japan Agency for Medical Research and Development |
| NCT04527081 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2020 | AnGes, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnGes, Inc. | For profit | 3 | 3 | 2 | 2020 |
| Japan Agency for Medical Research and Development | Government | 2 | 0 | 2 | 2020 |
2 organizations
Page 1 / 1